
TO WHOM IT MAY CONCERN

3 June 2022

Via Email

To: Hellenic Urological Association
23 Ravine str, 11521 Athens-Greece

Re: Rezūm™ Water Vapour Therapy

Dear Sir/Madam:

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

The treatment options for BPH continue to see innovation with more modalities being available than ever before. Noticeably the newer category of minimally invasive therapies is becoming more popular to physicians and prospective patients for a variety of reasons. Rezūm is one of the more recent technologies available to treat BPH, first made accessible in the USA following FDA and CE mark approval and then launched in the UK in 2018, expanding further across Europe and the Middle East from 2019.


Rezūm Therapy provides significant, sustained improvement of lower urinary tract symptoms (LUTS) and quality of life for patients suffering from BPH out to 5 years post-procedure¹. Currently Rezūm is classified under the EAU guidelines for “Alternative ablative technologies under investigation”, whereby randomized controlled trials against a reference technique are needed to confirm the first promising clinical results and to evaluate mid- and long-term efficacy and safety of water vapour energy treatment. We are committed to research and the need for robust clinical data, in order to meet the the EAU requirements to enable guideline recommendations. We are currently sponsoring a RCT for REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (VAPEUR RCT). (ClinicalTrials.gov Identifier: NCT04838769).

Rezūm training is available to all physicians who have an interest in exploring the use or techniques of Rezūm in their practice and a physician must be certified before conducting Rezūm procedures. In Greece, to date we have certified 40 physicians and continue to make training available.

In addition, we advocate that treatment of patients should always be in line with clinical judgements and consider local patient selection criteria.

If you have any questions, please contact me on my mobile +30 695 661 4535 or email: donne.botha@bsci.com.

Sincerely,



Donne Botha
Boston Scientific
Sales Manager Urology Eastern Cluster

¹ McVary KT, Roehrborn C. Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Late-Breaking Abstract. J Urol. 2020 Apr;203(4):e1021